pharma · Agitation · Agitation,Psychomotor · BTAI
BioXcel Therapeutics
BioXcel Therapeutics is a pharma organization headquartered in New Haven, USA. It trades on NYSE under ticker BTAI. Primary therapeutic focus areas include Agitation, Agitation,Psychomotor, Alcohol Use Disorder (AUD), Sc
555 Long Wharf Dr, 12th floor, New Haven, Connecticut 06511, US HQ
2017 Founded
56 Employees
Public company Type
BTAI · NYSE Ticker
Company details
- Status
- Public
- HQ
- 555 Long Wharf Dr, 12th floor, New Haven, Connecticut 06511, US
- Founded
- 2017
- Employees
- 56
- Programs
- 17
- Drugs
- 9
- Patents
- 18
Sublingual film containing BXCL501 (Dexmedetomidine)
Phase 1 · small molecule · Agitation
Sublingual film containing BXCL501 (Dexmedetomidine) for Agitation is a Phase 1 program (small_molecule) at BioXcel Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code BXCL501-102
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- BioXcel Therapeutics
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Agitation
- Status
- completed
- Trials
- 1